Novo Nordisk A/S Fundamental Analysis (XETRA: NOVC.DE)
Novo Nordisk A/S Fundamental Analysis (XETRA: NOVC.DE)
Novo Nordisk A/S (XETRA: NOVC.DE) shows moderate financial fundamentals with a PE ratio of 36.60, profit margin of 36.03%, and ROE of 88.07%. The company generates $230.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 89.5/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze NOVC.DE's fundamental strength across five key dimensions:
Efficiency Score
ExcellentNOVC.DE demonstrates superior asset utilization.
Valuation Score
ModerateNOVC.DE shows balanced valuation metrics.
Growth Score
ModerateNOVC.DE shows steady but slowing expansion.
Financial Health Score
ModerateNOVC.DE shows balanced financial health with some risks.
Profitability Score
ExcellentNOVC.DE achieves industry-leading margins.
Key Financial Metrics
Is NOVC.DE Expensive or Cheap?
P/E Ratio
NOVC.DE trades at 36.60 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, NOVC.DE's PEG of -0.19 indicates potential undervaluation.
Price to Book
The market values Novo Nordisk A/S at 28.82 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 26.41 times EBITDA. This signals the market has high growth expectations.
How Well Does NOVC.DE Make Money?
Net Profit Margin
For every $100 in sales, Novo Nordisk A/S keeps $36.03 as profit after all expenses.
Operating Margin
Core operations generate 44.16 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $88.07 in profit for every $100 of shareholder equity.
ROA
Novo Nordisk A/S generates $26.61 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Novo Nordisk A/S generates strong operating cash flow of $107.82B, reflecting robust business health.
Free Cash Flow
Novo Nordisk A/S generates strong free cash flow of $69.32B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $15.58 in free cash annually.
FCF Yield
NOVC.DE converts 2.30% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
36.60
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.19
vs 25 benchmark
P/B Ratio
Price to book value ratio
28.82
vs 25 benchmark
P/S Ratio
Price to sales ratio
13.09
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.25
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.82
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.88
vs 25 benchmark
ROA
Return on assets percentage
0.27
vs 25 benchmark
ROCE
Return on capital employed
0.71
vs 25 benchmark
How NOVC.DE Stacks Against Its Sector Peers
| Metric | NOVC.DE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 36.60 | 32.14 | Worse (Expensive) |
| ROE | 88.07% | 550.00% | Weak |
| Net Margin | 36.03% | 30133.00% | Weak |
| Debt/Equity | 0.25 | 0.56 | Strong (Low Leverage) |
| Current Ratio | 0.82 | 5.70 | Weak Liquidity |
| ROA | 26.61% | 3.00% | Excellent |
NOVC.DE outperforms its industry in 2 out of 6 key metrics, particularly excelling in ROA, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Novo Nordisk A/S's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation